Hanuman .I just looked at the last 3 month of news Cytogenix had, they did alot of work.We should be seeing financing soon.Its very good the company has all these patents.
--------------------------------------------------------------------------------
Ownership: Public
Symbol: CYGX (NASDAQ Bulletin Board)
--------------------------------------------------------------------------------
CytoGenix, Inc. (CYGX) Antimicrobial Compound Is Active Against The Most Resistant Bacteria Strain
CytoGenix Inc. (OTCBB:CYGX) announces the results of a pre-clinical proof-of-concept study demonstrating that its antimicrobial compound CY401 is active against Vancomycin-resistant Staphylococcus aureus (VRSA). This laboratory study demonstrated that CytoGenix CY401 inhibits growth of VRSA, bacteria that are resistant to approved doses of all antibiotic products.
(See Story from BioSpace.com) (10/26/04)
CytoGenix, Inc. (CYGX) Announces A Pre-Clinical Research Agreement With Baylor College of Medicine To Test An Agent Against Deadly Resistant Bacteria
CytoGenix Inc. (OTCBB:CYGX) announces that it has entered into an agreement with the Section of Pediatric Infectious Diseases of Baylor College of Medicine, for mice and cell studies using the company's new antimicrobial agent against a highly dangerous strain of Staphylococcus aureus bacteria.
(See Story from BioSpace.com) (10/21/04)
CytoGenix, Inc. (CYGX) Files U.S. Patent Application For New Class Of Antibacterial Agent
CytoGenix Inc. (OTCBB:CYGX) announces the filing on Sept. 28, 2004, of a patent application with the U.S. Patent and Trademark Office for an invention titled A Novel Genomic Approach Identifies Bacterial DNA-Dependent RNA Polymerase as the Target of an Antibacterial Oligodeoxynucleotide, RBL1.
(See Story from BioSpace.com) (9/30/04)
NASA Contractor Senior Scientist Joins CytoGenix, Inc. (CYGX)
CytoGenix Inc. (OTCBB:CYGX) announces that Kurt L. Berens has agreed to join the company as Vice President of Product Development. Formerly a Section Manager for Wyle Laboratories, Cellular and Biomedical Group at NASA-Johnson Space Center, Houston, Berens has over fifteen years of clinical research experience.
(See Story from BioSpace.com) (9/14/04)
CytoGenix, Inc. (CYGX) CEO Dr. Malcolm Skolnick Invited To Participate In Corporate Governance Panel
CytoGenix Inc. (OTCBB:CYGX) announces that Dr. Malcolm Skolnick, CytoGenix CEO, was invited to participate with other Houston business leaders in a panel discussion of corporate integrity issues, the Sarbanes-Oxley Corporate Fraud and Accountability Act of 2002, and how these impact the conduct and cost of doing business.
(See Story from BioSpace.com) (9/8/04)
CytoGenix, Inc. (CYGX) Initiates Planned Expansion Of Its Scientific Staff
CytoGenix Inc. (OTCBB:CYGX) announces the expansion of its product development efforts with the addition of Dr. Frederic Kendirgi to the company's scientific staff. Dr. Kendirgi has broad experience in developing virology and immunology assays for protein function and expression vectors. He received a Ph.D. in biochemistry and molecular biology from the University of Calgary, and he has authored five scientific papers.
(See Story from BioSpace.com) (8/26/04)
CytoGenix, Inc. (CYGX) President Interviewed By WallStreetReporter.com
CytoGenix Inc. (OTCBB:CYGX) today announced that Dr. Malcolm Skolnick, chairman, president and CEO was interviewed by WallStreetReporter.com a leading financial news and information portal.
(See Story from BioSpace.com) (8/13/04)
CytoGenix, Inc. (CYGX) President Interviewed By CEOcast
CytoGenix Inc. (OTCBB:CYGX) today announced that Dr. Malcolm Skolnick, chairman, president and CEO was interviewed by CEOcast on Aug. 10, 2004.
(See Story from BioSpace.com) (8/12/04)
CytoGenix, Inc. (CYGX) Announces Successful Completion Of Pre-Clinical Anti-Herpes Safety Studies
CytoGenix, Inc. (OTCBB:CYGX) announced the successful completion of pre-clinical animal safety studies. These standard studies show that the company's lead DNA anti-herpes topical compound is safe in three species of animals. A third party laboratory conducted the tests operating under FDA Good Laboratory Practices (GLP) regulations and following United States Pharmacopeia (USP) testing standards for topical products.
(See Story from BioSpace.com) (8/3/04)
CytoGenix, Inc. (CYGX) Files International Patent Applications For New Class Of Antibacterial And Antifungal Agents
CytoGenix Inc. (OTCBB:CYGX) announced today that it has filed new patent applications for Nucleotides for Prevention and Treatment of Bacterial and Fungal Pathologies under the Patent Cooperation Treaty (PCT) of the World Intellectual Property Organization (WIPO).
News 
Market Data 
Discover 
AI
